章博士（John Zhang)在生物醫(yī)學(xué)科學(xué)和大分子抗體藥學(xué)工藝技術(shù)研究有超過25年的工作經(jīng)驗(yàn)。他不但在美國(guó)大學(xué)擔(dān)任過教授，從事口腔腫瘤發(fā)生治療方面教學(xué)與系統(tǒng)基礎(chǔ)研究。并在美國(guó)的大型生物制藥公司（Lonza, Altria and Bio-Techne )擔(dān)任資生科學(xué)家與高級(jí)管理職位。 他在生物藥制造工藝技術(shù)領(lǐng)域逐步建立了強(qiáng)大的能力并且知識(shí)面非常廣博。??????????? 章博士在2016年1月受邀作為高級(jí)副總裁進(jìn)入中國(guó)藥企工作。他成功領(lǐng)導(dǎo)了齊魯藥業(yè)集團(tuán)的工藝與生產(chǎn)團(tuán)隊(duì)，完成了多個(gè)仿制單克隆抗體項(xiàng)目工藝開發(fā)與生產(chǎn)以提供臨床研究所需用藥。其中負(fù)責(zé)的一個(gè)工藝驗(yàn)證項(xiàng)目已經(jīng)成功地投入商業(yè)性生產(chǎn)。????????????????????
在2018-2020年期間，他去百濟(jì)神州制藥公司（BeiGene Ltd）為建立廣州抗體工廠建設(shè)工藝團(tuán)隊(duì)的建設(shè)與早期自主研發(fā)項(xiàng)目的推進(jìn)做出了重要貢獻(xiàn)。? 2020年7月，他加入了再鼎醫(yī)藥作為大分子藥學(xué)副總裁，全面負(fù)責(zé)公司大分子藥學(xué)。他負(fù)責(zé)公司大分子抗體工藝開發(fā)與擔(dān)任再創(chuàng)蘇州生物制藥公司的企業(yè)負(fù)責(zé)人，組織實(shí)施生產(chǎn)運(yùn)行，為公司自主研發(fā)研發(fā)項(xiàng)目提供臨床用藥。?????????????? ?
由于章博士擁有廣泛的生物藥學(xué)方面的專業(yè)知識(shí)，所有工作的公司他都受邀提供藥學(xué)相關(guān)專業(yè)知識(shí)與建議，對(duì)公司引進(jìn)國(guó)外項(xiàng)目，提供十分重要的藥學(xué)評(píng)估。
Dr. Zhang (John Zhang) has more than 25 years of working experience in biomedical sciences and Biologics. Prior to his industrial tenure positions, he used to work as a professor in university (University of Illinois at Chicago) and engaged in systematic studies in the originals and treatment of oral tumors.? He also holds various senior management positions at large pharmaceutical companies in United States (Lonza, Altria and Bio-Techne).? He has gradually established strong capabilities in the field of biopharmaceutical manufacturing technology and has accumulated wide range of knowledge.?
Dr. Zhang returned to work as a Sr. VP of Biologics for Chinese pharmaceutical company (Qilu Pharmaceutical Group) in Jan. 2016. He successfully led the teams working on process development and manufacturing operations. Under his leadership, multiple bio-similar mAb projects have been successfully approved for clinical studies. One of leading project under his directly engaging in PCS and PV has been successfully approved for commercial manufacturing in 2019.
In 2018-2020, Dr. Zhang started his journey in Beigene Ltd as a VP of Manufacturing Technology. During his tenure at Beigene, Dr. Zhang made great contributions to the construction of BeiGene Manufacturing plant at early stage and the establishment of the Biologics CMC teams at Guangzhou Manufacturing factory. Meanwhile, he has been in charge of PD and Production team providing drug substances required for internal research projects at Suzhou Biologics Pilot Plant.
In July 2020, he joined Zai Lab as a vice president of Biologics CMC, responsible for company's Biologics process development at Shanghai site and also a head of Suzhou Biologics Pilot plant responsible for DS & DP supply for clinical studies of company's internal research and development projects.?????????????? Due to his comprehensive knowledge in Biologics CMC, he has been invited to participate in the evaluations of most external Biologics projects potentially license-in for all companies he work for.